Navigation Links
Anti-clotting agent does not improve outcomes of patients with severe pneumonia
Date:2/22/2011

aimed to assess the efficacy and safety of tifacogin as adjunct therapy in sCAP.

"CAP remains the most common cause of death from infection," Dr. Wunderink said. "Anti-clotting therapies are sought to complement the antimicrobial treatment and supportive care measures that are currently used for sCAP patients."

In this study, researchers enrolled 2,138 sCAPpatients from 188 centers from 2005 to 2008, randomizing them to receive tifacogin or placebo intravenously for four days. Although two doses of tifacogin (0.025 mg/kg/h and 0.075 mg/kg/h) were initially included in the study, the higher dose was dropped early on when no benefit was demonstrated.

At the end of the study although tifacogin did show an effect on clotting measures in the blood, the researchers found mortality rates and the incidence of adverse events were similar in both the tifacogin and placebo groups.

Dr. Wunderink said the study's negative results could be due to several factors.

"The coagulation and inflammatory responses may have been irreversibly activated before tifacogin was administered, or specific processes that occur during CAP may have blunted the effect of the drug," he said. "However, the most logical explanation is that tissue factor activation, while important, may not be a critical step in the pathogenesis of sCAP mortality."

Although the study showed no benefit associated with the use of tifacogin in sCAP patients, Dr. Wunderink said it clearly demonstrates the need for additional research to improve sCAP mortality rates.

"CAPTIVATE represents the largest clinical trial of severe CAP performed to date," Dr. Wunderink said. "The design and execution of the study demonstrates that a more homogeneous population with a single source ofinfection, rather than a more generic sepsis population, can be defined, which will be of benefit for future studies.

"Although theprimary end-point was not achieved, this study d
'/>"/>

Contact: Brian Kell
bkell@thoracic.org
212-316-6442
American Thoracic Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Anti-Clotting Drug May Work Better After Hip Replacement
2. Extended use of anti-clotting drug helps some bedridden patients
3. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
4. VCU Massey first to combine targeted agents to kill multiple myeloma cells
5. SNM applauds FDA advisory committee recommendation for approval of Alzheimers imaging agent
6. Study provides molecular rationale for combining targeted agents to treat breast cancer
7. Colorectal cancer patients with gene mutation show better response to cancer agent
8. Targeted agent shows promise for chronic lymphoid leukemia
9. Agent Orange exposure linked to Graves disease in Vietnam veterans, UB study finds
10. New Research Uncovers Elusive Target of Antifungal Agent
11. Compound enhances cancer-killing properties of agent in trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Sound Telecom, a ... solutions, and cloud-based business communication systems, has unveiled an ... about HIPAA-compliant Secure Text Messaging .” The piece examines ... need to do to remain compliant with HIPAA and ... the article and C.O.O. at Sound Telecom, opens with ...
(Date:8/27/2014)... August 27, 2014 Dr. Stewart ... Center see multitudes of patients suffering from impaired vision. ... Cataract vision correction surgery . Recently, Dr. Shofner ... information during an eye exam and also online. To ... top five myths about glaucoma. , 1)    Myth: People with ...
(Date:8/27/2014)... ANS is pleased to ... anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). ... new medical therapy and will begin extending this new ... NovoTTF™ Therapy is a portable, non-invasive anti-mitotic system approved ... age and older. It is a treatment option for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The federal ... http://www.consumerinjurylawyers.com/DePuy/ ) has extended the deadline for plaintiffs to ... August 2014 Order issued by U.S. District Judge David ... to enroll in the DePuy ASR Settlement Program must ... Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – ...
(Date:8/27/2014)... August 27, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, reports ... for discovery procedures, specifically Collection and Preservation of Evidence, ... transvaginal mesh devices. (MDL No. 2187, In Re: C.R. ... United States District Court, Southern District or West Virginia; ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... , , , , ... Outstanding Debt to be Reduced by Approximately $54.8 Million , ... , Company to Book Approximately $8.2 Million Estimated ... by Approximately $45.4 Million , , , , ...
... ... been among the first to use NeoPlas Innovation,s new protocol. , ... Nashville, Tenn. (Vocus) June 16, 2009 -- With an ... his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and ...
... as Unwarranted, Withdraws Two Cold Remedy Nasal Products Citing Commitment ... June 16 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... from the U.S. Food and Drug Administration about two of ... Gel and Zicam Cold Remedy Swabs. The warning letter cited ...
... CHICAGO, June 16 David O. Barbe, M.D., a ... the Board of Trustees of the American Medical Association. , ... , , "I am honored to be elected to the ... representing physicians as the AMA and the nation focus on health-care ...
... change" says new leader of American medicine , , ... cardiologist from Bryan, Texas, was inaugurated today as the 164th ... and most influential physician organization. , , (Logo: ... In his inaugural address as AMA president, Dr. Rohack spoke ...
... Food and Drug Administration (FDA) today advised consumers to stop ... cold remedies under the Zicam(R) brand because the use of ... of smell (a condition called anosmia ). ... zinc ingredient, The Quigley Corporation (Nasdaq: QGLY ), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 4Health News:Inoperable Colon Cancer Responds to New Treatment 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:AMA Inaugurates J. James Rohack as President 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 3
(Date:8/27/2014)... , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... development of drugs targeting unmet needs in oncology, autoimmune and ... 2014 Health Care Conference to be held at The New ... on September 3-4, 2014. Alan Fuhrman ... and its lead drug candidate, quizartinib, at 1:10 p.m. ET ...
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... 27, 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ... , today announced the results of the Company,s 2014 Annual ... Beijing , PRC. The required quorum, a majority ... The Company,s shareholders approved the following proposals:  , ... , Simon Anderson , Kenneth Lee and ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, has entered into ... Solutions Australasia Pty. Ltd., based in Newport, Victoria, ...
... Aug. 12, 2011 Southern Research Institute today announced ... named Vice President of the Drug Discovery Division. Dr. ... research and target identification and lead discovery ... diseases and neurological diseases and disorders. ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Australia and New Zealand 2Misonix Announces New Distribution Agreement for Australia and New Zealand 3Southern Research Names Mark Suto Vice President of Drug Discovery 2
... innovator of suction products in the U.S. ... and assure that their quality meets or ... and directly support our full line of ... and Poole Tip Suction handles, suction canisters, ...
Touch-Trol Suction Catheter Mini-Tray...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Suction Catheter Kits with Sterile Saline (Bottle)...
Medicine Products: